Enhanced ECT for Depression
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators or your physician for guidance.
What data supports the idea that Enhanced ECT for Depression is an effective treatment?
The available research shows that Enhanced ECT, specifically Focal Electrically Administered Seizure Therapy (FEAST), is effective for treating depression. Studies indicate that FEAST has antidepressant effects and causes fewer cognitive side effects compared to traditional ECT. For example, one study found that FEAST had less impact on cognitive functions while still being effective in reducing symptoms of depression. Additionally, FEAST was compared to another form of ECT, Right Unilateral Ultrabrief Pulse ECT, and was found to have similar antidepressant effects but with reduced cognitive side effects. This suggests that FEAST is a promising treatment option for depression with potentially fewer negative impacts on memory and thinking.12345
What safety data is available for Enhanced ECT for Depression?
The safety data for Enhanced ECT, specifically Focal Electrically-Administered Seizure Therapy (FEAST), indicates that it may have reduced cognitive side effects compared to traditional ECT. Multiple studies have explored its safety, feasibility, and cognitive effects. Initial trials suggest that FEAST is safe and feasible, with potentially fewer cognitive adverse effects than traditional ECT methods. However, these findings are based on preliminary data and further research is needed to confirm these results.13456
Is Enhanced Spatial Targeting in ECT (FEAST) a promising treatment for depression?
What is the purpose of this trial?
The purpose of this research study is to find an alternative version of ECT that reduces the negative side effects (mainly memory loss) while still providing patients with relief from depressive symptoms. Previous forms of ECT may use Bilateral (electrodes on both sides of the head) or Right Unilateral (RUL) (electrodes on one side of the head). Our research focuses on adjusting the placement of electrodes on one side of the head in order to better stimulate the Prefrontal Cortex (PFC) of the brain. By more specifically targeting the PFC, it is predicted that participants will receive the same benefit as ECT but will have fewer negative side effects after the treatment, mainly less memory loss. All other aspects of the treatment will be similar to regular, clinical ECT, including anesthesia and recovery monitoring. To accomplish this stimulation, an adjusted MECTA Spectrum 5000Q device will be used. If successful, this research study will demonstrate a way to improve ECT procedures for all patients suffering from Major Depressive Disorder by minimizing side effects and maintaining or improving efficacy.
Research Team
Ziad Nahas, MD
Principal Investigator
University of Minnesota
Eligibility Criteria
This trial is for adults with major depressive disorder who have a significant level of depression and are deemed suitable for ECT by their doctor. They must be able to consent to treatment. Excluded are those with recent substance abuse, certain psychiatric or neurological conditions, pregnancy, or recent ECT.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Baseline assessments for cognition, mood, and quality of life, including a baseline MRI
Treatment
Participants receive FEAST or RP FEAST treatments 3 times per week, with dose adjustments based on response
Follow-up
Follow-up assessments of cognition, mood, and quality of life after the 6th, 12th, and 15th treatments
Optional MRI Follow-up
Optional follow-up MRI to assess changes post-treatment
Treatment Details
Interventions
- Enhanced Spatial Targeting in ECT Utilizing FEAST
Enhanced Spatial Targeting in ECT Utilizing FEAST is already approved in United States, European Union, Canada for the following indications:
- Major Depressive Disorder
- Severe Mental Health Conditions
- Schizophrenia
- Major Depressive Disorder
- Severe Mental Health Conditions
- Schizophrenia
- Major Depressive Disorder
- Severe Mental Health Conditions
- Schizophrenia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor